Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/GHA865. CME/MOC/AAPA credit will be available until January 6, 2025. Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer
▶︎

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer

Updates in Systemic Therapy for Breast Cancer 2/8/23
▶︎

Updates in Systemic Therapy for Breast Cancer 2/8/23

Targeting With Precision in Advanced Ovarian Cancer
▶︎

Targeting With Precision in Advanced Ovarian Cancer

Innovation Takes the Stage in HNSCC
▶︎

Innovation Takes the Stage in HNSCC

Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Delivery in Multiple Myeloma
▶︎

Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Delivery in Multiple Myeloma

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Novel ER-Targeting Therapies
▶︎

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Novel ER-Targeting Therapies

Pathway to Precision in Ovarian Cancer
▶︎

Pathway to Precision in Ovarian Cancer

Bladder Cancer Breakthroughs Unpacked
▶︎

Bladder Cancer Breakthroughs Unpacked

"La guerra di Trump? Nelle nostre tasche: tra riarmo e finanza siamo il bancomat di Wall Street"
▶︎

"La guerra di Trump? Nelle nostre tasche: tra riarmo e finanza siamo il bancomat di Wall Street"

AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD
▶︎

AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD

Tamoxifen for Breast Cancer: A Complete Guide
▶︎

Tamoxifen for Breast Cancer: A Complete Guide

Donor Profiling and Cell Isolation for Scalable Cell and Gene Therapy Manufacturing
▶︎

Donor Profiling and Cell Isolation for Scalable Cell and Gene Therapy Manufacturing

Watch Drs. Saad & Barata on prostate cancer updates at #AUA26: https://bit.ly/Prostate26DC-Y
▶︎

Watch Drs. Saad & Barata on prostate cancer updates at #AUA26: https://bit.ly/Prostate26DC-Y

Modern Interventions in Neuroendocrine Carcinoma: DLL3-Directed BiTE Therapy in Community Settings
▶︎

Modern Interventions in Neuroendocrine Carcinoma: DLL3-Directed BiTE Therapy in Community Settings

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic Therapy
▶︎

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic Therapy

Maximizing Outcomes in Non-Muscle Invasive Bladder Cancer
▶︎

Maximizing Outcomes in Non-Muscle Invasive Bladder Cancer

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02
▶︎

SABCS 2023 HER2+ Breast Cancer Highlights – APHINITY Sub-analysis, KATHERINE update, HER2CLIMB-02

Drs. Kopetz, Eng & Fakih discuss #CRC updates at #ASCO26: bit.ly/2026CRC-Y
▶︎

Drs. Kopetz, Eng & Fakih discuss #CRC updates at #ASCO26: bit.ly/2026CRC-Y

Dr. Marion Saville, Cervical cancer elimination: The need for high-quality, low-cost PoC HPV assays
▶︎

Dr. Marion Saville, Cervical cancer elimination: The need for high-quality, low-cost PoC HPV assays

The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking NewTreatment Opportunities
▶︎

The Promise of Oral Therapy for HER2-Mutated NSCLC: Unlocking NewTreatment Opportunities